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Abstract
The CmeABC efflux pump in Campylobacter jejuni confers resistance to structurally divergent antimicrobials,
and inhibition of CmeABC represents a promising strategy to control antibiotic-resistant Campylobacter.
Antisense peptide nucleic acids (PNAs) targeting the three components of CmeABC were evaluated for
inhibition of CmeABC expression. The result revealed a synergistic effect of the PNAs targeting CmeA and
CmeB on sensitizing C. jejuni to antibiotics. This finding further demonstrates the feasibility of using PNAs to
potentiate antibiotics against antibiotic-resistant Campylobacter.
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The CmeABC efflux pump in Campylobacter jejuni confers resistance to structurally divergent antimicrobials, and inhibition of
CmeABC represents a promising strategy to control antibiotic-resistant Campylobacter. Antisense peptide nucleic acids (PNAs)
targeting the three components of CmeABCwere evaluated for inhibition of CmeABC expression. The result revealed a synergis-
tic effect of the PNAs targeting CmeA and CmeB on sensitizing C. jejuni to antibiotics. This finding further demonstrates the
feasibility of using PNAs to potentiate antibiotics against antibiotic-resistant Campylobacter.
Campylobacter jejuni is a major food-borne pathogen account-ing for 400 to 500 million cases of diarrhea each year world-
wide (1). This organism is increasingly resistant to clinically
important antibiotics, particularly fluoroquinolone (FQ) antimi-
crobials (2). The CmeABC efflux pump in Campylobacter confers
resistance to a broad range of antimicrobials and toxic com-
pounds (3). In addition, this efflux pump functions synergistically
with othermechanisms (e.g., spontaneousmutations in antibiotic
targets) inmediating high-level resistance to antibiotics (3). Cme-
ABC is also important for bile resistance and is essential for Cam-
pylobacter colonization in the intestinal tract of animal hosts (4).
Due to the significant role of CmeABC in antibiotic resistance,
inhibition of CmeABC represents a promising strategy to control
antibiotic-resistant Campylobacter. Efflux pump inhibitors, such
as phenyl-arginine--naphthylamide (PAN), have been evalu-
ated to inhibit antibiotic efflux in Campylobacter (5). The general
findings are that PAN has a significant impact on erythromycin
(Ery) but has limited or no effect on theMICs of FQ antimicrobi-
als in Campylobacter (5–7). Peptide nucleic acids (PNAs) are syn-
thetic homologs of nucleic acids inwhich the phosphate backbone
of polynucleotides is replaced by a flexible pseudopeptide polymer
(8). PNAs function as antisense agents by binding specifically to
complementary sequences in DNA and RNA and inhibiting gene
expression and/or translation (9). Recently, we showed that a
CmeA-specific PNA reduced the expression of CmeA and increase
the susceptibility ofC. jejuni strains resistant to both ciprofloxacin
(Cipro) and erythromycin (Ery) (10). However, it remains un-
known if PNAs against other components of CmeABC are also
effective in inhibiting the function of the efflux pump and if com-
binatorial use of PNAs against different components of the efflux
system enhances the inhibitory effect.
In this study, we designedmultiple PNAs against all three com-
ponents of the CmeABC efflux pump based on the genome se-
quence of C. jejuni NCTC 11168 and evaluated their activities
individually and in combination using a wild-type strain (NCTC
11168), a Cipro-resistant mutant (62301R33), and an Ery-resis-
tant mutant (JL272). The CmeA-specific PNA sequence is TCAT
GGTTTTGC, the CmeB-specific PNA sequence is ATTATTGTG
CTC, and the CmeC-specific PNA sequences are CATGAACCT
TAC, CCTTACCTCTTT, and TATTCATGAACC. A negative-
control PNA (ACACACACACAC)was also synthesized. All PNAs
were conjugated to the oligopeptide KFFKFFKFFK to improve
PNA entry into bacterial cells (11).
The PNAs were added to Campylobacter cultures in Mueller-
Hinton (MH) broth at different concentrations (0, 1, 2, and 4
M). To detect if the PNAs inhibited CmeABC expression, SDS-
PAGE and Western blotting were performed with antibodies
against CmeA, CmeB, and CmeC as described previously (10).
Addition of the CmeA PNA to culture media reduced the expres-
sion of CmeA, as well as that of CmeB and CmeC (Fig. 1A). The
CmeB PNA reduced the expression of CmeB, but it did not affect
the expression of CmeC and CmeA (Fig. 1A). Unlike the CmeA
and CmeB PNAs, none of the three CmeC PNAs examined in this
study altered the expression of CmeC as determined by Western
blotting (partly shown in Fig. 1A). Combination of the CmeA and
CmeB PNAs reduced the expression of all three proteins of the
efflux pump. Compared with the individual PNAs, the combina-
tion of CmeA and CmeB PNAs produced stronger inhibition of
CmeABC expression (Fig. 1A). Densitometric analysis of the blot-
ting results also confirmed the synergistic effect of the PNA com-
bination on the expression of CmeABC (Fig. 1B). The negative-
control PNA did not affect the expression of CmeABC (data not
shown). None of the examined PNAs affected the expression of
the major outer membrane protein (MOMP), which was used as
an internal control (Fig. 1A).
It should be pointed out that CmeC is an N-glycosylated pro-
tein and shows as two bands, resulting from different glycosylated
forms (3). The finding that the tested CmeC PNAs had no effect
on the translation of CmeC was surprising, and the exact reason
for this observation is unknown. One possibility is that the CmeC
mRNA has unique secondary structures that prevent the binding
of PNAs. Alternatively, the ribosome binding site (RBS) of CmeC
is embedded in the coding sequence of CmeB, and the translation
from CmeB might alleviate the inhibition of CmeC by PNAs.
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To assess whether the PNAs against CmeA, CmeB, and CmeC
affected the susceptibility of C. jejuni to antimicrobials, we mea-
sured the MICs of Cipro and Ery in the presence of the PNAs
either individually or in combination using a microtiter broth
dilution method described previously (10). The key results are
shown in Table 1. At 1 and 2 M, none of the PNAs altered the
susceptibility of NCTC 11168 to Cipro and Ery. At 4 M, the
CmeA-specific PNA and the CmeB-specific PNA increased
the susceptibility of NCTC 11168 to Cipro and Ery by 2-fold, but
the CmeC PNAs did not show any effects, consistent with the
results from Western blotting. Notably, the combination of the
two PNAs against CmeA and CmeB at 1 M each resulted in 16-
and 4-fold decreases in theMICs of Cipro and Ery, respectively, in
NCTC 11168 (Table 1). At higher concentrations (2 and 4 M),
this combination further sensitizedNCTC11168 to the antibiotics
(Table 1). We also evaluated the PNAs in a Cipro-resistant strain
(62301R33) and an Ery-resistant strain (JL272). Isolate 62301R33
has the C257T mutation in gyrA, which contributes to the high-
level resistance to Cipro (12), while JL272 has the A2074G muta-
tion in 23S rRNA, mediating high resistance to erythromycin (12,
13). In both cases, the target mutations work synergistically with
CmeABC in conferring high-level resistance to the antibiotics. In
62301R33, the PNAs against CmeA and CmeB reduced the Cipro
MIC 8- and 2-fold, respectively, while the combination of the two
resulted in 16-fold reduction in the MIC. In JL272, the two PNAs
each produced a 2-fold reduction in EryMIC and combination of
the two reduced the MIC by 4-fold.
These results indicate that CmeABC PNAs potentiate the ac-
tivities of antibiotics in both wild-type and antibiotic-resistant
strains of C. jejuni. The results also suggest that the inhibition of
CmeABC expression and function depends on the target gene,
with CmeA and CmeB PNAs showing the highest efficiency. Im-
portantly, this study demonstrates a synergistic effect of the PNAs
against CmeA andCmeB in sensitizingC. jejuni to antibiotic when
used in combination. These findings further illustrate the feasibil-
ity of using PNAs to potentiate antibiotics against antibiotic-resis-
tant Campylobacter. Considering that PNAs are resistant to
proteases and nucleases and are stable in acidic pH (12, 14), anti-
CmeABC PNAs may be potentially used as an adjunctive therapy
for antibiotic-resistant Campylobacter in vivo.
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